Using CRISPR gene editing, a team from Children’s Hospital of Philadelphia (CHOP) and Penn Medicine have thwarted a lethal lung disease in an animal model in which a harmful mutation causes death within hours after birth.
This proof-of-concept study, published today in Science Translational Medicine, showed that in uteroediting could be a promising new approach for treating lung diseases before birth.
“The developing fetus has many innate properties that make it an attractive recipient for therapeutic gene editing,” said study co-leader William H. Peranteau, MD, an investigator at CHOP’s Center for Fetal Research, and a pediatric and fetal surgeon in CHOP’s Center for Fetal Diagnosis and Treatment. “Furthermore, the ability to cure or mitigate a disease via gene editing in mid- to late gestation before birth and the onset of irreversible pathology is very exciting. This is particularly true for diseases that affect the lungs, whose function becomes dramatically more important at the time of birth.”
The lung conditions the team is hoping to solve — congenital diseases such as surfactant protein deficiency, cystic fibrosis, and alpha-1 antitrypsin — are characterized by respiratory failure at birth or chronic lung disease with few options for therapies. About 22 percent of all pediatric hospital admissions are because of respiratory disorders, and congenital causes of respiratory diseases are often lethal, despite advances in care and a deeper understanding of their molecular causes. Because the lung is a barrier organ in direct contact with the outside environment, targeted delivery to correct defective genes is an attractive therapy.
“We wanted to know if this could work at all,” said study co-leader Edward E. Morrisey, PhD, a professor of Cardiovascular Medicine in the Perelman School of Medicine at the University of Pennsylvania. “The trick was how to direct the gene-editing machinery to target cells that line the airways of the lungs.”
The researchers showed that precisely timed in utero delivery of CRISPR gene-editing reagents to the amniotic fluid during fetal development resulted in targeted changes in the lungs of mice. They introduced the gene editors into developing mice four days before birth, which is analogous to the third trimester in humans.
The cells that showed the highest percentage of editing were alveolar epithelial cells and airway secretory cells lining lung airways. In 2018, a team led by Morrisey identified the alveolar epithelial progenitor (AEP) lineage, which is embedded in a larger population of cells called alveolar type 2 cells. These cells generate pulmonary surfactant, which reduces surface tension in the lungs and keeps them from collapsing with every breath. AEPs are a stable cell type in the lung and turn over very slowly, but replicate rapidly after injury to regenerate the lining of the alveoli and restore gas exchange.
In a second experiment, the researchers used prenatal gene editing to reduce the severity of an interstitial lung disease, surfactant protein C (SFTPC) deficiency, in a mouse model that has a common disease-causing mutation found in the human SFTPC gene. One hundred percent of untreated mice with this mutation die from respiratory failure within hours of birth. In contrast, prenatal gene editing to inactivate the mutant Sftpc gene resulted in improved lung morphology and survival of over 22 percent of the animals.
Future studies will be directed toward increasing the efficiency of the gene editing in the epithelial lining of lungs as well as evaluating different mechanisms to deliver gene editing technology to lungs. “Different gene editing techniques are also being explored that may one day be able to correct the exact mutations observed in genetic lung diseases in infants,” Morrisey said.
The Latest on: Gene editing
via Google News
The Latest on: Gene editing
- Gene Editing Service Market Analysis, Segments, Growth and Value Chain 2021 - 2026 | Impact of COVID-19 Pandemicon June 24, 2020 at 9:01 am
Kenneth Research has published a detailed report on Gene Editing Service Market which has been categorized by market ...
- The Alliance for Regenerative Medicine Announces Its 2020 Cell & Gene Meeting on the Mesa Goes Virtualon June 24, 2020 at 8:48 am
The Alliance for Regenerative Medicine (ARM), an international multi-stakeholder advocacy organization representing the regenerative medicine and advanced therapy sector, today announced a new virtual ...
- First Patient To Receive Gene Editing Treatment For Sickle Cell Doing Well In 2020on June 23, 2020 at 5:10 pm
The first patient to receive a special gene editing treatment for sickle celldisease is surviving ― and even thriving ― a year later.Victoria Gray, 34, whose story has been chronicled by NPR for the ...
- Light-activated 'CRISPR' enables fast, precise gene editing and detection of DNA repairon June 23, 2020 at 1:05 pm
In a series of experiments co-funded by the National Science Foundation, scientists at Johns Hopkins have used light as a trigger to make quick, precise cuts in the genomic material of human cancer ...
- AAV Gene Therapy Pioneer Jude Samulski Develops Proprietary Regulated Gene Editing Systemon June 23, 2020 at 6:48 am
Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Jude Samulski, PhD, President, Chief Scientific Officer ...
- A Year In, 1st Patient To Get Gene-Editing For Sickle Cell...on June 23, 2020 at 2:58 am
She's the first person with a genetic disorder to get treated in the United States with the revolutionary gene-editing technique called CRISPR. And as the one-year anniversary of her landmark ...
- News Brief: Trump Trip To Arizona, Primary Elections, Gene-Editing Patienton June 23, 2020 at 2:04 am
President Trump travels to Arizona to talk about his southern border wall. Five states hold primary elections. And, an update on the first U.S. patient to get treatment from a gene-editing technique.
- A Year In, 1st Patient To Get Gene Editing For Sickle Cell Disease Is Thrivingon June 23, 2020 at 2:04 am
Since receiving a landmark treatment with the gene-editing tool CRISPR, a sickle cell patient has the strength to care for herself and her children — while navigating the pandemic.
- APLU, AAVMC form gene editing in animal ag task forceon June 22, 2020 at 12:03 pm
The Association of Public and Land-grant Universities (APLU) and the Association of American Veterinary Medical Colleges (AAVMC) have established a task force to create recommendations for regulating ...
- Multiplexed heritable gene editing using RNA viruses and mobile single guide RNAson June 1, 2020 at 8:34 am
An in planta gene editing approach was developed wherein Cas9 transgenic plants are infected with an RNA virus that expresses single guide RNAs (sgRNAs). The sgRNAs are augmented with sequences ...
via Bing News